Exicure, Inc. (XCUR): Price and Financial Metrics
XCUR Price/Volume Stats
| Current price | $0.37 | 52-week high | $1.78 |
| Prev. close | $0.40 | 52-week low | $0.37 |
| Day low | $0.37 | Volume | 28,900 |
| Day high | $0.43 | Avg. volume | 28,212 |
| 50-day MA | $0.62 | Dividend yield | N/A |
| 200-day MA | $0.91 | Market Cap | 3.20M |
XCUR Stock Price Chart Interactive Chart >
XCUR Stock Summary
- With a market capitalization of $4,064,704, EXICURE INC has a greater market value than just 2.17% of US stocks.
- XCUR's current price/earnings ratio is 1.33, which is higher than only 0.71% of US stocks with positive earnings.
- Revenue growth over the past 12 months for EXICURE INC comes in at 584.21%, a number that bests 98.66% of the US stocks we're tracking.
- Stocks that are quantitatively similar to XCUR, based on their financial statements, market capitalization, and price volatility, are ACLS, CMBM, SCKT, GPRO, and HYPR.
- Visit XCUR's SEC page to see the company's official filings. To visit the company's web site, go to www.exicuretx.com.
XCUR Valuation Summary
- XCUR's EV/EBIT ratio is 2.7; this is 78.74% lower than that of the median Healthcare stock.
- XCUR's price/sales ratio has moved down 12.4 over the prior 67 months.
Below are key valuation metrics over time for XCUR.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| XCUR | 2023-11-20 | 0.2 | 0.5 | 1.6 | 2.7 |
| XCUR | 2023-11-17 | 0.2 | 0.5 | 1.7 | 2.8 |
| XCUR | 2023-11-16 | 0.2 | 0.5 | 1.6 | 2.7 |
| XCUR | 2023-11-15 | 0.2 | 0.5 | 1.6 | 2.7 |
| XCUR | 2023-11-14 | 0.2 | 0.5 | 1.6 | 2.7 |
| XCUR | 2023-11-13 | 0.2 | 0.5 | 1.7 | 2.8 |
XCUR's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- XCUR has a Quality Grade of C, ranking ahead of 38.19% of graded US stocks.
- XCUR's asset turnover comes in at 0.039 -- ranking 338th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows XCUR's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.039 | 1 | -0.674 |
| 2021-03-31 | 0.085 | 1 | -0.500 |
| 2020-12-31 | 0.161 | 1 | -0.327 |
| 2020-09-30 | 0.157 | 1 | -0.336 |
| 2020-06-30 | 0.152 | 1 | -0.444 |
| 2020-03-31 | 0.133 | 1 | -0.757 |
XCUR Price Target
For more insight on analysts targets of XCUR, see our XCUR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $10.00 | Average Broker Recommendation | 1.38 (Strong Buy) |
Exicure, Inc. (XCUR) Company Bio
Exicure, Inc. operates as a clinical stage bio-technology company. The Company develops a new class of immunomodulatory and gene regulating drugs against validated targets, as well as addresses diseases such as oncology, immunology, and dermatology. Exicure serves customers in the United States.
Latest XCUR News From Around the Web
Below are the latest news stories about EXICURE INC that investors may wish to consider to help them evaluate XCUR as an investment opportunity.
Lacklustre Performance Is Driving Exicure, Inc.'s (NASDAQ:XCUR) 25% Price DropExicure, Inc. ( NASDAQ:XCUR ) shares have had a horrible month, losing 25% after a relatively good period beforehand... |
Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of DirectorsCHICAGO, August 23, 2023--Exicure, Inc. announces appointment of new CEO and CFO and changes to Board of Directors. |
Exicure First Half 2023 Earnings: US$1.38 loss per share (vs US$3.71 loss in 1H 2022)Exicure ( NASDAQ:XCUR ) First Half 2023 Results Key Financial Results Net loss: US$10.2m (loss narrowed by 36% from 1H... |
Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateCHICAGO, August 11, 2023--Exicure, Inc. reports second quarter 2023 financial results and provides corporate update. |
Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate UpdateCHICAGO, July 14, 2023--Exicure, Inc. reports first quarter 2023 financial results and provides corporate update. |
XCUR Price Returns
| 1-mo | -39.36% |
| 3-mo | -55.43% |
| 6-mo | -61.05% |
| 1-year | -63.37% |
| 3-year | -99.18% |
| 5-year | -99.66% |
| YTD | -67.83% |
| 2022 | -81.03% |
| 2021 | -88.58% |
| 2020 | -38.11% |
| 2019 | -19.21% |
| 2018 | N/A |
Continue Researching XCUR
Want to do more research on Exicure Inc's stock and its price? Try the links below:Exicure Inc (XCUR) Stock Price | Nasdaq
Exicure Inc (XCUR) Stock Quote, History and News - Yahoo Finance
Exicure Inc (XCUR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...